

GHANA INACTIVATED POLIO VACCINE (IPV) SUPPORT

This Decision Letter sets out the Terms of a Programme.

1. Country: Ghana																			
2. Grant Number: 1518-GHA-25c-X / 15-GHA-08h-Y																			
3. Date of Decision Letter: 5 February 2015																			
4. Date of the Partnership Framework Agreement: 11 July 2014																			
5. Programme Title: NVS, IPV Routine																			
6. Vaccine type: Inactivated Polio Vaccine (IPV)																			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID																			
8. Programme Duration²: 2015 - 2018																			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <i>Please note that endorsed or approved amount for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>																			
	2015	2016	2017	Total ³															
Programme Budget (US\$)	US\$427,500	US\$1,215,500	US\$1,058,000	US\$2,701,000															
10. Vaccine Introduction Grant: US\$646,000																			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴ <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 60%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 20%;">2015</th> <th style="width: 20%;">2016</th> </tr> </thead> <tbody> <tr> <td>Number of IPV vaccines doses</td> <td style="text-align: center;">367,900</td> <td style="text-align: center;">1,046,700</td> </tr> <tr> <td>Number of AD syringes</td> <td style="text-align: center;">339,900</td> <td style="text-align: center;">954,200</td> </tr> <tr> <td>Number of safety boxes</td> <td style="text-align: center;">3,750</td> <td style="text-align: center;">10,500</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td style="text-align: center;">US\$427,500</td> <td style="text-align: center;">US\$1,215,500</td> </tr> </tbody> </table>					Type of supplies to be purchased with Gavi funds in each year	2015	2016	Number of IPV vaccines doses	367,900	1,046,700	Number of AD syringes	339,900	954,200	Number of safety boxes	3,750	10,500	Annual Amounts (US\$)	US\$427,500	US\$1,215,500
Type of supplies to be purchased with Gavi funds in each year	2015	2016																	
Number of IPV vaccines doses	367,900	1,046,700																	
Number of AD syringes	339,900	954,200																	
Number of safety boxes	3,750	10,500																	
Annual Amounts (US\$)	US\$427,500	US\$1,215,500																	
12. Procurement agency: UNICEF .																			
13. Self-procurement: Not applicable																			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This is the amount that Gavi has approved.

<p>14. Co-financing obligations: N/A Gavi's usual co-financing requirements do not apply to IPV. However, Ghana is encouraged to contribute to vaccine and/or supply costs for IPV.</p>					
<p>15. Operational support for campaigns: N/A</p>					
<p>16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:</p> <table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or equivalent</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or equivalent	To be agreed with Gavi Secretariat
Reports, documents and other deliverables	Due dates				
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat				
<p>17. Financial Clarifications: Not applicable</p>					
<p>18. Other conditions: If Ghana envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Ghana. Update on implementation of recommendations indicated in the signed Aide-Mémoire as soon as possible. Please send a copy of insurance policy certifying that vaccines and devices are insured as stipulated and required by the Partnership Framework Agreement.</p>					

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

5 February 2015